Melatonin Potentiates the Neuroprotective Properties of Resveratrol Against Beta-Amyloid-Induced Neurodegeneration by Modulating AMP-Activated Protein Kinase Pathways by Kwon, Kyoung Ja et al.
Copyright © 2010 Korean Neurological Association  127
Print ISSN 1738-6586 / On-line ISSN 2005-5013
10.3988/jcn.2010.6.3.127
ORIGINAL ARTICLE
J Clin Neurol 2010;6:127-137
Melatonin Potentiates the Neuroprotective Properties  
of Resveratrol Against Beta-Amyloid-Induced Neurodegeneration   
by Modulating AMP-Activated Protein Kinase Pathways
Kyoung Ja Kwon, PhD
a*; Hee-Jin Kim, MD, PhD
b*; Chan Young Shin, PhD
c; Seol-Heui Han, MD, PhD
a
aDepartments of Neurology and 
cPharmacology, Center for Geriatric Neuroscience Research, Institute of Biomedical Science and 
Technology, School of Medicine, Konkuk University, Seoul, Korea 
bDepartment of Neurology, Hanyang University College of Medicine, Seoul, Korea
Received	 February 10, 2010
Revised	 April 15, 2010
Accepted	 April 15, 2010
*These authors equally contributed.
Correspondence
Seol-Heui Han, MD, PhD
Departments of Neurology,
Center for Geriatric 
Neuroscience Research, 
Institute of Biomedical Science and 
Technology, School of Medicine,
Konkuk University, 
1 Hwayang-dong, Gwangjin-gu,
Seoul 143-701, Korea 
Tel    +82-2-2030-7561
Fax   +82-2-2030-7899
E-mail    alzdoc@kuh.ac.kr
Background and PurposezzRecent studies have demonstrated that resveratrol (RSV) reduces 
the incidence of age-related macular degeneration, Alzheimer’s disease (AD), and stroke, while mel-
atonin (MEL) supplementation reduces the progression of the cognitive impairment in AD pa-
tients. The purpose of this investigation was to assess whether the co-administration of MEL and 
RSV exerts synergistic effects on their neuroprotective properties against β-amyloid (Aβ)-induced 
neuronal death.
MethodszzThe neuroprotective effects of co-treatment with MEL and RSV on Aβ1-42 -induced 
cell death, was measured by MTT reduction assay. Aβ1-42 caused an increase in intracellular lev-
els of reactive oxygen species (ROS), as assessed by H2-DCF-DA dye, and a reduction of total glu-
tathione (GSH) levels and mitochondrial membrane potential, as assessed using monochlorobi-
mane and rhodamine 123 fluorescence, respectively. Western blotting was used to investigate the 
intracellular signaling mechanism involved in these synergic effects.
ResultszzWe treated a murine HT22 hippocampal cell line with MEL or RSV alone or with both 
simultaneously. MEL and RSV alone significantly attenuated ROS production, mitochondrial mem-
brane-potential disruption and the neurotoxicity induced by Aβ1-42. They also restored the Aβ1-
42-induced depletion of GSH, back to within its normal range and prevented the Aβ1-42-induced 
activation of glycogen synthase kinase 3β (GSK3β). However, co-treatment with MEL and RSV 
did not exert any significant synergistic effects on either the recovery of the Aβ1-42-induced de-
pletion of GSH or on the inhibition of Aβ1-42-induced GSK3β activation. Aβ1-42 treatment in-
creased AMP-activated protein kinase (AMPK) activity, which is associated with subsequent neu-
ronal death. We demonstrated that MEL and RSV treatment inhibited the phosphorylation of AMPK.
ConclusionszzTogether, our results suggest that co-administration of MEL and RSV acts as an ef-
fective treatment for AD by attenuating Aβ1-42-induced oxidative stress and the AMPK-depen-
dent pathway.  J Clin Neurol 2010;6:127-137
Key Wordszz  melatonin, resveratrol, neuroprotection, reactive oxygen species, 
glycogen synthase kinase 3β, AMP-activated protein kinase.
Introduction 
Alzheimer’s disease (AD) is a progressive and age-related 
neurodegenerative disorder, that is, characterized clinically by 
irreversible cognitive dysfunction, memory loss, and behav-
ioral changes.
1 These features are accompanied by specific 
pathologic changes in the brain, which manifest as the extra-
cellular deposition of a fibrillar form of amyloid-β1-42 peptide 
(Aβ1-42) constituted senile plaques. Aβ1-42 is the cleavage 
fragment made by proteinases from the amyloid precursor 
protein, which exerts neurotoxic effects concerned with neu-
roinflammation, immune activation, and oxidative stress and 
thus has been considered to play a critical role in the patho-
genesis of AD.
2 However, the mechanism underlying this Melatonin Enhances the Neuroprotective Effects of Resveratrol Against β-Amyloid-Induced Neurodegeneration
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β-amyloid peptide (Aβ) neurotoxicity remains to be fully elu-
cidated. There is increasing evidence that Aβ alters Ca
2+ ho-
meostasis, mitochondrial dysfunction, and apoptosis, and in-
creases the intracellular level of reactive oxygen species (ROS) 
in the AD brain.
It is well known that the neuronal cell death induced by Aβ1-
42 is effected via several pathogenic mechanisms, such as the 
induction of glycogen synthase kinase-3β (GSK3β).
3 There 
are several recent lines of evidence that neurodegeneration, 
such as in AD and stroke, is associated with the activation of 
AMP-activated protein kinase (AMPK).
4 However, the signal 
mechanisms underlying Aβ neurotoxicity have not been elu-
cidated. Thus, in this investigation, we explored the relation-
ship between GSK3β and AMPK signaling in Aβ1-42-induced 
neurotoxicity.
One of the potential candidates, that can regulate the Aβ-in-
duced neuroinflammatory response, is melatonin (N-acetyl-5-
methoxy-tryptamine, MEL), which is the main secretory pro-
duct of the pineal gland,
5 and participates in various physio-
logical functions including the control of seasonal repro-
duction, regulation of circadian rhythms and body tempera-
ture via receptors,
6 and acts a potent free-radical scavenger and 
antioxidant.
7 The special features of MEL include its role in 
the regulation of the immune response and exertion of cyto-
protective properties in various neurodegeneration models, 
both in vivo and in cell cultures.
8,9 It was recently suggested 
that MEL plays a critical role as an antioxidant and neuropro-
tector in aging and AD. Levels of MEL decrease with age, and 
patients with AD experience an even greater reduction in this 
hormone. Clinical reports indicate that MEL supplementation 
improves sleep and slows down the progression of cognitive 
impairment in patients with AD. It also effectively prevents 
Aβ-mediated neuronal cell death via its antioxidant and anti-
amyloid properties. Interest in MEL has grown following st-
udies in which it was established that 1) MEL can easily cross 
the blood  brain barrier;10 2) the endogenous production of 
MEL falls dramatically with increasing age;11 3) high doses of 
MEL do not present any harmful side-effects;12 and 4) MEL 
acts as a free-radical scavenger in most tissues.
13 On the basis 
of these data, MEL has been proposed as a preventive treat-
ment against neurodegenerative disorders; however, the pro-
tective mechanism underlying its actions remains to be eluci-
dated.
Another plausible and wide-studied candidate is resvera-
trol (trans-3,4,5’-Trihydroxystilbene, RSV), which is a natural 
polyphenolic compound found mainly in the skin of grapes 
and nuts, pomegranates, and Polygonum cuspidatum, a com-
ponent of Chinese herbal medicines, and is present at high 
levels in red wine. RSV is a competent estrogenic product, ex-
hibiting protective effects in cardiovascular diseases, cancer, 
and neurodegenerative diseases,
14 partly as a result of its anti-
oxidative, anti-inflammatory, and anti-mutagenic activities.
15 
There is evidence for beneficial effects of RSV in neurodegen-
erative conditions, such as cerebral ischemia,
16 Parkinson’s 
disease (PD),
17 AD,
18 and normal aging.
19 The action of RSV ma-
nifests as the regulation of the activities and expression levels 
of enzymes and proteins associated with the survival signal, 
regulation of ion channels, and anti-oxidative actions.
20 RSV 
also activates the sirtuin categorized class III histone deacety-
lases. Sirtuins play a key role in various cellular processes, in-
cluding lifespan extension in response to caloric restriction 
(CR).
21,22 However, the mechanisms involved in these protec-
tive effects of RSV on neurons are not fully understood.
Based on these observations, we investigated whether com-
bination with MEL and RSV can attenuate Aβ1-42-induced 
neuronal death. In particular, we focused on the effects of com-
bined treatment on oxidative  stress-induced parameters, such 
as mitochondrial membrane potential (Δψm), GSK3β, and AM-
PK signaling associated with energy homeostasis and cell 
survival.
Methods
Materials
Pregnant Sprague  -Dawley (SD) rats were obtained from Ori-
ent Bio (Seoul, Korea) and minimum essential medium (MEM) 
was purchased from JBI (Seoul, Korea). Dulbecco’s modified 
Eagle’s medium (DMEM), fetal bovine serum, and antibiotics 
were purchased from Gibco (Gaithersburg, MD, USA), and 
Aβ1-42 peptide was purchased from BACHEM (Bubendorf, 
Switzerland). RSV, N-acetyl cysteine (NAC), 5-aminoimi-
dazole-4-carboxamide-1-β-D-ribofuranoside (AICAR), ade-
nine 9-β-D-arabinofuranoside (Ara-A), and MEL were purchas-
ed from Sigma Chemical (St. Louis, MO, USA). PD98059 (PD) 
and SB203580 (SB) were purchased from Calbiochem, EMD 
Biosciences (La Jolla, CA, USA), and SP600125 (SP) and Tro-
lox were purchased from Biomol (Plymouth Meeting, PA, 
USA). Monochlorobimane (mBCl) was purchased from Fluka 
(St. Louis MO, USA) and H2-2’7’  dichlorofluorescein diacetate 
dye (H2DCF-DA), dihydroethidium (DHE), and rhodamine 
123 were purchased from Molecular Probes (Eugene, OR, USA).
Cell culture
All experimental procedures were carried out using protocols 
approved by the Institutional Animal Care and Use Commit-
tee of Konkuk University. Murine HT22 hippocampal cells 
were cultured with DMEM supplemented with 10% fetal bo-
vine serum, 100   U/mL penicillin, and 100 mg/mL streptomy-
cin. The cells were rinsed twice with serum-free medium and 
then detached with 0.2% trypsin with ethylenediaminetet-Kwon KJ et al.
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raacetic acid, and re  plated at a low density (5,000   cells/cm
2) in 
a 24-well or 6-well plate (Becton-Dickinson, Franklin Lakes, 
NJ, USA). The re-plated cells were incubated for 24  -h before 
the experiment.
Primary hippocampal neuronal cultures were obtained from 
the dissociated embryonic day-18 hippocampus of pregnant 
SD rats. Briefly, the hippocampus, freed of meninges, was me-
chanically dissociated and gently triturated thrice with a flame-
polished Pasteur pipette in the culture medium (Eagle’s MEM 
supplemented with 20 mM glucose). The cells were seeded 
onto plates coated with 100 μg/mL poly-D-lysine and 200   μg/mL 
laminin in the culture medium supplemented with 5% fetal 
bovine serum, 5% horse serum, and 2   mM glutamine. The cul-
tures were maintained at 37ºC in a humidified incubator con-
taining 5% CO2. For pure neuron cultures, 5 μM cytosine-β-
arabinofuranoside was added after 3 days. The cultured cells 
were used after 7   days, by which time the neurons had differ-
entiated from neuronal precursor cells.
Preparation of the Aβ1-42 oligomer
Aβ1-42 was dissolved to a 10-  mM stock solution in dimeth-
ylsulfoxide (DMSO, Sigma Chemical, SIGMA, St. Louis, USA) 
and diluted in phosphate-buffered saline (PBS) to a final Aβ 
concentration of 1 mM. Aggregation of the Aβ1-42 peptide-
was achieved by incubating the cells with the diluted Aβ for 
3-  h at 37ºC, as described previously.
23
Experimental procedure
MEL and RSV were dissolved in ethanol and DMSO, respec-
tively, at final ethanol and DMSO concentrations of 0.1% and 
0.01%, respectively. The effects of MEL and RSV on neuro-
nal cell death were determined by evaluating the following: 
1) viability of the cells, assessed using a 3-(4,5-dimethylthi-
azxol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay; 
2) measurement of intracellular ROS; 3) measurement of to-
tal glutathione (GSH); 4) change in the Δψm; and, 5) activa-
tion of the intracellular signaling molecules, such as mito-
gen-activated protein kinase (MAPKs), GSK3β, and AMPK. 
The concentration-dependency of the effects of MEL and RSV 
on Aβ1-42-induced neuronal death was evaluated in HT22 
hippocampal cells, incubated for 24-h and 48  -h with various 
concentrations of MEL (1, 10, 50, 100, and 500 μM) and RSV 
(0.1, 1, 5, 10, and 20 μM). 
Cells were pretreated with MEL for 1  -h before Aβ1-42, and 
RSV was added along with Aβ1-42. To establish the participa-
tion of AMPK in the neuroprotective effects of MEL and RSV, 
the cells were incubated for 1-h with the AMPK activator; 
AICAR (10, 100, or 1,000 μM) or AMPK inhibitor; Ara-A (10, 
100, or 1,000 μM), followed by incubation with Aβ1-42, MEL, 
and RSV for 24-h.
Assessment of cell viability
Cell viability was also assessed by the MTT assay. MTT is a 
water-soluble tetrazolium salt that is reduced by metabolically 
viable cells to a colored, water-insoluble formazan salt. MTT 
(5   mg/mL) was added to the cell-culture medium. After incu-
bating the plates at 37ºC for 2-  h in a 5% CO2 atmosphere, the 
assay was suspended and the MTT-containing medium was 
replaced with DMSO. The absorbance was read at 570 nm with 
a microplate reader (Molecular Devices, Palo Alto, CA, USA). 
The percentage of surviving neurons was measured relative 
to control values (untreated cells, 100%).
Measurement of intracellular ROS
Intracellular ROS formation was measured by fluorescence 
using H2DCF-DA.
24 This non-fluorescent dye freely perme-
ates into cells, where it de-esterifies to form the ionized  free 
acid (dichlorofluorescein), which reacts with ROS to form 
the fluorescent 2’,7’-  dichlorofluorescein (DCF). After the drug 
treatment, cultures were washed with Hank’s balanced aque-
ous salts solution (HBSS) containing 120   mM NaCl, 5   mM 
KCl, 1.6   mM MgCl2, 2.3   mM CaCl2, 15   mM glucose, 20   mM 
HEPES, and 10   mM NaOH, loaded with 20   μM H2DCF-DA 
and 20% Pluronic F-127 for 30   min at 37ºC, and then washed 
again with HBSS and kept at room temperature for an addi-
tional 30 min to allow for the complete de-esterification of 
the dye. 
DCF fluorescence was analyzed using a fluorescence plate 
reader (Spectramax Gemini EM, Molecular Devices) at exci-
tation and emission wavelengths of 490 and 530   nm, respec-
tively, with a fluorescence microscope.
Measurement of Δψm
Changes in Δψm were estimated by the uptake of a cell-per-
meant, lipophilic, cationic, fluorescent dye, rhodamine 123, 
which enters the mitochondria as a result of the highly nega-
tive Δψm. Depolarization of Δψm results in the loss of rho-
damine 123 from the mitochondria, resulting in a decrease in 
the intracellular fluorescence. Treated cells were incubated 
with rhodamine 123 (10   μM) at 37ºC for 20   min, after which 
they were washed twice with PBS and then observed under a 
fluorescence microscope (LSM10, Carl Zeiss, Dublin, CA, USA).
Determination of GSH
To measure the total GSH content, the cells cultured in six-
well plates were first washed with PBS, and 20   μM mBCl 
with PBS was added and incubated for 20   min at 37ºC, and 
then washed again with PBS. Fluorescence was monitored at 
excitation and emission wavelengths of 390 and 480   nm, re-
spectively, using a fluorescence plate reader (Spectramax Ge-
mini EM, Molecular Devices).Melatonin Enhances the Neuroprotective Effects of Resveratrol Against β-Amyloid-Induced Neurodegeneration
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Western blot analysis
After treatment with Aβ1-42, MEL, and RSV for a specific 
time period, the cells were harvested and homogenized in 100 
μL/well sodium dodecylsulfate (SDS) sample buffer contain-
ing 62.5   mM Tris-HCl (pH  6.8), 2% (w/v) SDS, 10% glycer-
ol, 50   mM dithiothreitol, 0.1% (w/v) bromophenol blue, and 
1   mM sodium orthovanadate. After boiling for 5   min, equal 
amounts of protein were subjected to 10% SDS  polyacrylamide 
gel electrophoresis for 140   min, after which the separated 
proteins were transferred electrophoretically to nitrocellulose 
membranes (Whatman, Dassel, Germany) for 20   min. The blot 
was blocked with 5% non-fat, dried milk at room tempera-
ture and subsequently incubated overnight at 4ºC with the 
following antibodies: anti-p38, anti-p44/42, anti-c  Jun  N  ter-
minal kinases (JNKs), anti-GSK3β, anti-AMPKα, anti-phos-
pho-p38 (Thr180/Tyr182), anti-phospho-p44/42 (Thr202/Tyr-
204), anti-phospho-JNK (Thr183/Tyr185), anti-phospho-
GSK3β (Ser9), anti-phospho-AMPKα (Thr172) (1:1,000), 
and anti  -β-actin. After incubation with horseradish peroxidase-
conjugated secondary antibodies at room temperature for 1-h, 
the bands were detected with an enhanced chemiluminescence 
detection system (Amersham Biosciences, Piscataway, NJ, 
USA) and analyzed using an LAS-3000 image detection sys-
tem (Fuji, Tokyo, Japan).
Statistical analysis
Data are expressed as the mean±S.E.M values. Differences 
between groups were examined for statistical significance 
using one-way analysis of variance with Student’s t-test and 
the level of statistical significance was set at p<0.05.
Results
Effects of MEL and RSV on Aβ1-42-induced 
cytotoxicity in HT22 hippocampal neuronal cells
We investigated the synergistic effects of combined treatment 
with MEL and RSV against Aβ1-42-induced neurotoxicity, us-
ing an HT22 hippocampal neuronal cell line, primary hippo-
campal neurons, and an MTT assay. Aβ1-42 treatment induced 
neuronal cell death in a concentration-dependent manner 
(data not shown). We tested the protective effects of MEL and 
RSV at a fixed Aβ1-42 concentration of 2   μM. The concentra-
tion ranges of MEL and RSV were 1-500   μM and 0.1-20   μM, 
respectively. MEL and RSV prevented Aβ1-42-induced neu-
rotoxicity in HT22 hippocampal neuronal cell line in a con-
centration-dependent manner (Fig.   1A and B). The protective 
effects of MEL and RSV were also observed in rat primary 
hippocampal neurons (data not shown). Maximum protection 
against Aβ1-42-induced neurotoxicity was achieved with 500 
  μM of MEL and 20   μM of RSV. Low concentrations of MEL 
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Fig.   1. Protective effects of MEL and RSV on Aβ1-42-induced cyto-
toxicity in HT22 hippocampal neuronal cells. A and B: HT22 cells 
were treated with the indicated concentrations of MEL (1, 10, 50, 
100, and 500   μM) and RSV (0.1, 1, 10, and 20   μM) in the absence 
or presence of Aβ1-42 for 24  h at 37°C. The viability of HT22 cells 
was determined by the MTT reduction assay after treatment with 
MEL, RSV, and Aβ1-42. MEL was administered 1-  hr before Aβ1-42 
treatment, while RSV was added to the medium along with Aβ1-42. 
C: Co  treatment effects of MEL (1 and 10   μM) and RSV (0.1 and 1   
μM). Data are expressed as the mean±S.E.M values of three ex-
periments. The data shown are representative of five independent 
experiments that gave similar results. **p<0.01 vs. control, 
†p<0.05, 
‡p<0.01 vs. Aβ1-42 alone. MEL: melatonin, RSV: resveratrol, Aβ: β- 
amyloid. Kwon KJ et al.
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(1-10   μM) and RSV (0.1-1   μM) did not prevent Aβ1-42-induc-
ed cytotoxicity. 
However, co-treatment with MEL and RSV at concentra-
tions that when treated via monotherapy provided no protec-
tion synergistically prevented Aβ1-42-induced cytotoxicity 
(Fig.   1C). These results suggest that co  treatment with MEL 
and RSV is more effective in preventing Aβ1-42  induced cy-
totoxicity than either MEL or RSV alone.
Effects of MEL and RSV on Aβ1-42-induced 
oxidative stress in HT22 hippocampal 
neuronal cells
It is relatively well known that the toxicity of Aβ1-42 is medi-
ated through the production of ROS and oxidative stress-in-
duced damage. Hence, we investigated whether the neuro-
protective effects of MEL and RSV blocked Aβ1-42-induced 
oxidative stress and increased the anti-oxidative properties in 
the hippocampal neuronal cells. Cellular oxidative stress was 
determined spectrophotometrically with excitation at 490   nm 
and emission at 530   nm emission, based on ROS-mediated 
conversion of DCFH to fluorescent DCF. Aβ1-42 at about 2 
μM increased the intracellular ROS production by about 
1.8-folds after 6  -h in the hippocampal neuronal cells. MEL 
and RSV at the tested  concentrations profoundly reduced the 
Aβ1-42-induced production of ROS to control levels (Fig.   2A) 
without affecting basal levels of ROS production. Trolox 
(100   μM, a water  soluble vitamin E analog), which was used 
as a positive control, reduced the Aβ1-42   induced increase in 
ROS by about 40%. This indicates that MEL and RSV have 
potent antioxidant properties even compared with Trolox in 
Aβ1-42-stimulated HT22 hippocampal cells. In this study, 
even co-treatment with MEL and RSV did not induce a reduc-
tion of the ROS production below control levels, suggesting 
that MEL and RSV do not perturb the normal range of ROS 
production, or even probably ROS-mediated physiological 
intracellular signaling. The Aβ1-42  induced increase in ROS 
as measured by DHE was blocked by cotreatment with MEL 
and RSV (data not shown). 
Anti-oxidative properties of MEL and RSV 
on Aβ1-42-induced oxidative stress in HT22 
hippocampal neurons
It has been suggested that the antioxidative properties of MEL 
and RSV are mediated by the prevention of GSH depletion. 
The effects of MEL and RSV on the level of GSH, an essen-
tial endogenous antioxidant, were examined by studying the 
effects of MEL and RSV on Aβ1-42-induced GSH depletion. 
After 12-  h of Aβ1-42 treatment, mBCl was applied to the 
medium and the total GSH levels were determined spectro-
photometrically with excitation and emission wavelengths of 
390 and 485 nm, respectively. In the hippocampal neuronal 
cells, treatment with Aβ1-42 led to a decrease of about 20% 
in intracellular GSH levels within 12-  h. Treatment with MEL 
and RSV restored that GSH depletion to at least the control 
levels (Fig.   2B). As a result of ROS production, either MEL 
or RSV was sufficient to prevent GSH depletion; co  treatment 
with MEL and RSV did not further increase intracellular 
GSH levels. 
Effects of MEL and RSV on Δψm
It has been reported that both MEL and RSV, prevent mito-
chondrial oxidative stress. Thus, we examined the effects of 
MEL, RSV, and a combination of both on Δψm as one of the 
markers of mitochondrial function. Δψm was assessed using 
rhodamine 123 fluorescence dye. Aβ1-42 treatment induced 
a loss of about 20  % of Δψm at 6   h, MEL and RSV prevented 
that loss (Fig.   2C and D). MEL and RSV alone and co  treatment 
with MEL and RSV together did not elevate Δψm over con-
trol values.
Effects of MEL and RSV on Aβ1-42-induced
MAPK signaling
Oxidative stress is one of the major stimuli for MAPK signal-
ing cascades, such as extracellular signal related kinase (ERK) 
1/2 and p38. It has been shown that Aβ1-42 treatment leads 
to activation of ERK1/2, which is related to cell death. The ef-
fects of MEL and RSV on the MAPK activation induced by 
Aβ1-42, the cell lysates, with Aβ1-42 peptide with or without 
MEL and RSV for 30   min. The results were analyzed by West-
ern blotting using anti-phospho-ERK1/2 (Thr202/Tyr204), 
anti-phospho-p38 (Thr180/Tyr182), and anti-phospho-JNK 
(Thr183/Tyr185) antibodies. Aβ1-42 treatment resulted in an 
increase in phosphorylated ERK1/2 and p38 MAPK; this ac-
tivation was prevented by MEL and RSV in hippocampal neu-
ronal cells (Fig.   3A). 
Combination treatment with MEL and RSV inhibited p38 
phosphorylation, but did not prevent ERK activation. Aβ1-42-
induced neurotoxicity was inhibited by 20   μM PD and 20   μM 
SB, which are inhibitors of ERK and p38 MAPK, respective-
ly. Activation of ERK was blocked by its inhibitor, 20   μM PD, 
and phosphorylation of p38 MAPK was prevented by the in-
hibitor of p38 MAPK, 20   μM SB (Fig.   3B), but not by a JNK in-
hibitor, SP. These results provide further evidence that ERK1/2 
and p38 MAPK are associated with cell death in the presence 
of Aβ1-42. Moreover, our data demonstrate that the neuropro-
tective effects of MEL and RSV are mediated through the in-
hibition of ERK1/2 and p38 activity, and that the inhibitory ef-
fects of combination treatment with MEL and RSV on Aβ1-
42-induced neurotoxicity are, at least partially regulated, by p38 
MAPK.Melatonin Enhances the Neuroprotective Effects of Resveratrol Against β-Amyloid-Induced Neurodegeneration
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Fig.   2. Anti  oxidative properties of MEL and RSV on Aβ1-42-induced oxidative stress in HT22 hippocampal neuronal cells. MEL was adminis-
tered 1-h before Aβ1-42 treatment, while RSV was added to the medium along with the Aβ1-42. A: Effects of MEL and RSV on Aβ1-42-
induced increase in DCF fluorescence. RSV at the indicated concentration was applied concomitantly with 1   μM Aβ1-42 for 6-h in HT22 
cells. Intracellular ROS was evaluated by measuring H2DCF-DA fluorescence (490/530   nm), as described in the Materials and Methods. B: 
Effects of MEL and RSV on Aβ1-42-induced depletion of GSH. After 12-h of Aβ1-42 treatment, mBCl was applied to the medium and total 
GSH levels were determined spectrophotometrically at 390/480   nm. C: Effects of MEL and RSV on Δψm, as assessed by fluorescence mi-
croscopy using the fluorescence dye rhodamine 123, as described in the Materials and Methods. D: Measurement of Δψm by fluorospec-
trophotometry: MEL (100 μM), RSV (20 μM), M10R1 (MEL 10 μM+RSV 1 μM), and Tro (Trolox, 100 μM). Data are expressed as mean±S.
E.M values. The data shown are representative of five independent experiments that gave similar results. *p<0.05, **p<0.01 vs. control, 
†p< 
0.05, 
‡p<0.01 vs. Aβ1-42 alone. MEL: melatonin, RSV: resveratrol, Aβ: β- amyloid, DCF: dichlorofluorescein.
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Effects of MEL and RSV on Aβ1-42-induced 
GSK3β activation
Activation of GSK3β (Ser9) has been shown to be a key com-
ponent in the signaling pathways that underlie neurodegenera-
tive diseases. It is presumed that Aβ1-42 peptides are involved 
in the activation of GSK3β. Conversely, inactivation of GSK 
3β by phosphoinositide 3-kinase (PI3K)/Akt is an important 
neuroprotective mechanism. Hence, we examined whether MEL, 
RSV, and co  treatment with both induced inactivation of GSK 
3β. Aβ1-42 activated GSK3β, which could be prevented by 
MEL and RSV at 3  h after Aβ1-42 treatment (Fig.   4A). Either 
MEL or RSV alone was sufficient to inactivate GSK3β; com-
bination treatment with MEL and RSV did not show further 
inhibition of GSK3β activation. Aβ1-42-induced neuronal 
death was inhibited by treatment with LiCl (100   and, 1,000   μM), 
an inhibitor of GSK3β (Fig.   4B). These results suggest that 
the neuroprotective effects of MEL and RSV are mediated th-
rough an increase in inhibitory GSK3β phosphorylation.
Effects of MEL and RSV on AMPK signal 
activation
AMPK, a master sensor of energy balance in the peripheral tis-
Fig.   3. Effects of MEL and RSV on Aβ1-42-induced MAPK signaling. A: HT22 cells were incubated with 1-μM Aβ1-42 for 30-min in the pres-
ence or absence of MEL and RSV at the indicated concentrations, and then harvested for Western blot analysis. Immunoblots of lysates from 
treated HT22 cells were probed with phospho-ERK (Thr202/Tyr204), phospho-p38 (Thr180/Tyr182), and phospho-JNK (Thr183/Tyr185) anti-
bodies. As a loading control, total ERK/p38/JNK levels were also measured (lower panel). MEL and RSV attenuated Aβ1-42-induced activa-
tion of ERK and p38 MAPK. B: HT22 cells were treated with the indicated concentrations of PD (inhibitor of ERK), SB (inhibitor of p38 
MAPK), and SP (inhibitor of JNK) in the presence of Aβ1-42 for 24-h at 37°C. The viability of HT22 cells was determined by the MTT reduc-
tion assay after treatment with PD, SB, and SP with Aβ1-42. Treatment with these MAPK inhibitors blocked the Aβ1-42–induced activation of 
ERK/p38 MAPK. Data are expressed as the mean±S.E.M values of four independent experiments. **p<0.01 vs. control, 
†p< 0.05, 
‡p<0.01 vs. 
Aβ1-42 alone. MEL: melatonin, RSV: resveratrol, Aβ: β- amyloid, MAPK: mitogen-activated protein kinase, ERK: extracellular signal related kinase.
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sues, is phosphorylated and activated when the energy balance 
is low. RSV exerts multiple beneficial effects similar to those 
associated with CR, which improves neuronal health; AMPK 
is thought to be activated during CR. The neuroprotective pro-
perties of MEL and RSV led us to hypothesize that the neuro-
nal activation of AMPK is an important component of MEL 
and RSV activity. We therefore investigated whether AMPK 
was activated in HT22 hippocampal neuronal cells after Aβ1-
42 treatment and whether MEL or RSV alone or their co  treat-
ment inhibited AMPK activation. We found a robust increase 
in the pAMPK (Thr172) level 24-h after Aβ1-42 treatment (Fig. 
  5A); that elevation was maintained for 48   h. This phosphory-
lation of AMPK was blocked by treatment with either MEL or 
RSV; the inhibitory effects of MEL and RSV were augment-
ed by their co  treatment. Ara-A (100   μM, a pharmacological 
inhibitor of AMPK) prevented Aβ1-42-induced neurotoxicity 
in HT22 hippocampal neuronal cells (Fig.   5B), and the AMPK-
activating compound AICAR (100   μM) induced neuronal cell 
death in HT22 hippocampal cells (Fig.   5C). These findings 
demonstrate that neuronal inactivation of AMPK by MEL and 
RSV could affect neuronal energy homeostasis and contrib-
ute to the neuroprotective effects of MEL and RSV.
Discussion
The reported results show that MEL and RSV prevent the ac-
tivation of ERK, decrease ROS production, and restore GSH 
levels, and eventually attenuate neuronal cell death in hippo-
campal neuronal cells. However, although combination ther-
apy with MEL and RSV did not inhibit the activation of ERK, 
the production of ROS, or the depletion of GSH, it did exert a 
synergistic effect in reducing Aβ1-42-induced neurotoxicity. 
Aβ1-42 reduced the Δψm in the hippocampal neuronal cells, 
an action that was restored by cotreatment with MEL and RSV. 
The Aβ1-42   induced potentiation of GSK3β activity was in-
hibited by, either MEL or RSV alone. Similarly, the Aβ1-42-
induced activation of AMPK, a well-known regulator of ener-
gy homeostasis, was effectively prevented by treatment with 
either MEL or RSV. Importantly, combined treatment with MEL 
and RSV exerted a synergic reduction in AMPK activation.
The aggregation of soluble Aβ1-42 into oligomers/fibrils is 
one of the key pathological features of AD. We used Aβ1-42 of 
oligomers/fibrils made by incubation for 3   h at 37ºC, as desc-
ribed in the Materials and Methods. Although some batch  to-
batch variation was observed, the manufactured Aβ1-42 in-
duced neurotoxicity at a rate of 20-40% in HT22 hippocampal 
cells. Since MEL and its metabolites act as radical scavengesr, 
they can stimulate the activity of the mitochondrial  enzyme (NA-
DH-coenzyme Q reductase, and cytochrome C oxidase) asso-
ciated with oxidative phosphorylation,
25 and subsequently in-
crease ATP production. RSV, a polyphenolic compound, is known 
to be a potent activator of the sirtuin pathway and mimics the 
CR, both of which are associated with life-span expansion and 
aging. As a sirtuin activator, RSV is associated with the induc-
Fig.   4. Inhibitory effects of MEL and RSV on Aβ1-42-induced GSK-
3β activation. A: HT22 cells were incubated with 2 μM Aβ1-42 for 
6-  h in the presence or absence of the indicated concentrations of 
MEL and RSV, and harvested for Western blot analysis. Immunob-
lots of lysates from treated HT22 cells were probed with phospho-
GSK3β (Ser9) and GSK3β antibodies. Actin levels were measured 
for the confirmation of equal amount of protein loading (lower pan-
el). MEL and RSV inhibited the Aβ1-42-induced activation of GSK-
3β. B: HT22 cells were treated with indicated concentrations of LiCl 
(inhibitor of GSK3β) in the presence of Aβ1-42 for 24-  h at 37°C. The 
viability of HT22 cells was determined by the MTT reduction assay 
after treatment of LiCl with Aβ1-42. Data are expressed as the mean 
±S.E.M values of four independent experiments. **p<0.01 vs. con-
trol, 
†p<0.05, 
‡p<0.01 vs. Aβ1-42 alone; RSV (20 μM), MEL (100 μM), 
MR (MEL 10   μM+RSV 1 μM), Li (LiCl, 1   mM). MEL: melatonin, RSV: 
resveratrol, Aβ: β- amyloid.
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tion of genes for oxidative phosphorylation and mitochon-
drial biogenesis,
26 and can stimulate the preservation of brain 
mitochondrial function after hypoxia-  reperfusion. We expect-
ed that co-  treatment with MEL and RSV would be more pro-
tective against Aβ-induced neurotoxicity than either treat-
ment alone. Our data indicate that the neuroprotective effects 
of MEL and RSV are mediated via a decrease in ROS and an 
up  regulation of the antioxidant system, and that combination 
treatment with these two factors has a synergic effect on neu-
roprotection. Therefore, the actions of combined treatment 
with MEL and RSV could be beneficial for energy preserva-
tion and prevention of neuronal cell death. 
Combination treatment is a method of treating disease th-
rough the simultaneous use of a variety of drugs to eliminate 
or control the biochemical cause of the disease. The rationale 
for combination treatment is to use drugs that work via differ-
ent mechanisms of action without intolerable side effects. 
However, there have been few studies on combination treat-
ments. It was recently reported that combination therapy may 
be better than monotherapy in bipolar disorder in patients 
with bipolar disorder needing long-term treatment, the com-
bination of lithium plus valproate is more effective than val-
proate alone.
27 In the present study, we investigated the effects 
of combination treatment with MEL and RSV, which are well-
known neuroprotectors. 
Functionally, RSV exhibits histone deacetylase activity as 
a sirtuin activator (SIRT1), which is associated with CR and 
energy preservation, and so could have neuroprotective quali-
ties and promote longevity. SIRT1 is a class III histone deacet-
ylase and is essential for maintaining silent chromatin through 
the deacetylation of histones. MEL also is known to be an 
inducer of SIRT1.
28 It is possible that a combination of MEL 
and RSV exerts a synergic effect on SIRT1 activity, and that 
such combination treatment could thus induce a synergic ef-
fect on neuroprotection. Further study is needed to elucidate 
the exact mechanism underlying this potential effect.
Our results show that ERK activation is related to Aβ1-  42-
induced neurotoxicity in HT22 hippocampal neurons. Previ-
ous studies have shown that ERK activation is associated with 
cell survival and synaptic sprouting. However, it has been re-
ported recently that Aβ-induced neurotoxicity is regulated by 
the inhibition of ERK activation in rat organotypic hippocam-
Fig.   5. Effects of MEL and RSV on the activation of AMPK signaling. A: HT22 cells were incubated with 2   μM Aβ1-42 for 24-h in the presence 
or absence of the indicated concentrations of MEL and RSV, and then harvested for Western blot analysis. Immunoblots of lysates from 
treated HT22 cells were probed with phospho-AMPK (Thr172) and total AMPK antibodies. Actin levels were also measured to confirm equal 
amounts of protein loading (lower panel). MEL and RSV inhibited the Aβ1-42-induced activation of AMPK. B: HT22 cells were treated with 
Ara-A (inhibitor of AMPK) indicated concentrations, and Aβ1-42, or (C) the cells were treated with AICAR (activator of AMPK) without Aβ1-42 
for 24-  h at 37°C for the MTT assay. The viability of HT22 cells was determined by the MTT reduction assay. The inhibitor of AMPK blocked 
Aβ1-42-induced neuronal cell death and the activator of AMPK augmented Aβ1-42-induced neuronal cell death. Data are expressed as the 
mean±S.E.M values of three independent experiments. **p<0.01 vs. control, 
†p<0.05, 
‡p<0.01 vs. Aβ1-42 alone, 
§p<0.01 vs. drug only; RSV 
(20 μM), MEL (100   μM), MR (MEL 10 μM+RSV 1 μM), AIC (AICAR, 10-100 μM), Ara-A (10-100 μM). MEL: melatonin, RSV: resveratrol, Aβ: β- 
amyloid, ERK: extracellular signal related kinase, AMPK: AMP-activated protein kinase.
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pal slice cultures,
29 and that glutamate-induced toxicity is re-
lated to ERK activation.
30 Although co  treatment with MEL 
and RSV did not exert a synergistic effect in reducing ERK 
activation, our results demonstrate that Aβ1-42  induced neu-
rotoxicity could be mediated through ERK activation. 
AMPK has emerged as a master sensor of energy balance, 
and is phosphorylated and activated when energy balance is 
low. In other words, AMPK is activated by increasing the cel-
lular AMP: ATP ratio, whereupon it functions to help preserve 
cellular energy.
4 RSV is associated with CR, increasing the 
lifespan, and delaying the onset of diseases associated with 
aging. CR improves neuronal health, and a key enzyme th-
ought to be activated during CR is AMPK. Recent reports 
suggest that AMPK is highly expressed in cortical and hippo-
campal neurons under both normal and ischemic conditions. 
Pharmacological inhibition of AMPK reduces stroke damage, 
whereas the activation of AMPK by AICAR exacerbates that 
damage. We hypothesized that AMPK activation is an impor-
tant mediator of MEL and RSV actions in hippocampal neu-
ronal cells. Our results suggest that MEL and RSV manipulate 
the neuronal energy balance during Aβ1-42 treatment.
It was shown recently, that RSV activates AMPK signaling 
and that this activation of AMPK lowers extracellular Aβ ac-
cumulation.
31 However, MEL did not influence AMPK acti-
vation in C2C12 murine skeletal muscle cells.
32 Our results 
show that the Aβ1-42-induced activation of AMPK was in-
hibited by both monotherapy with either MEL or RSV and by 
their co-  treatment in the murine HT22 hippocampal cell line. 
Neuronal damage induced by Aβ1-42 activates AMPK, and 
combination treatment with MEL and RSV synergistically pre-
vented neuronal death by inhibiting the activation of AMPK. 
However, this effect on AMPK activation needs to be studied 
further.
In this study, MEL and RSV reversed the Aβ1-42   induced al-
teration in GSK3β, ERK, and AMPK activity. One obvious 
question pertains to the inter  relationship of the activities of th-
ese signaling molecules. For example, activation of the PI3K-
Akt-GSK3β pathway can regulate the AMPK pathway, and 
we reported that inhibition of GSK3β can activate ERK1/2 
in cultured rat astrocytes.
33 It is clear that understanding the 
nature of the extensive interplay between these diverse signal-
ing systems may help us to understand the mechanism under-
lying Aβ-dependent neurotoxicity as well as the protective 
mechanism induced by MEL and RSV.
In conclusion, our data demonstrate clearly that MEL and 
RSV have strong neuroprotective properties against Aβ1-42-
induced cytotoxicity in HT22 hippocampal neuronal cells, 
by attenuating oxidative stress through the induction of anti-
oxidants, such as GSH, and the inhibition of GSK3β activity. 
We also found that combined treatment with MEL and RSV 
exerts beneficial effects on neuronal survival by inhibiting the 
activation of AMPK. Our data suggest that co  treatment with 
MEL and RSV provides a useful therapeutic strategy against 
Aβ1-42-induced neurotoxicity.
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